Propel Bio Management, LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1969764) · Explore on the interactive board
Propel Bio Management, LLC disclosed 29 US equity positions worth $191.1m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 13, 2026). Its largest position is PAGPEUR at 16.2% of the reported book, followed by ACHV, CORT. The top ten holdings are 68.1% of the book, and the portfolio behaves like about 14 equal-weight positions. Versus the prior filing it opened 4 new positions, added to 11, reduced 10 and exited 13. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Propel Bio Management, LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 4 new, 11 added, 10 reduced, 13 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | PAGPEUR PLAINS GP HOLDINGS LP-CL | 16.2% | $30.9m | 1,272,360 | 0% | held | |
| 2 | ACHV ACHIEVE LIFE SCIENCES INC | 13.8% | $26.3m | 4,034,018 | 7% | added | |
| 3 | CORT CORCEPT THERAPEUTICS INC | Healthcare | 6.2% | $11.9m | 136,499 | -8% | reduced |
| 4 | PHAT PHATHOM PHARMACEUTICALS I | Healthcare | 6.0% | $11.4m | 1,050,358 | 25% | added |
| 5 | DCTH DELCATH SYSTEMS INC | 5.7% | $11.0m | 871,460 | -11% | reduced | |
| 6 | MIST MILESTONE PHARMACEUTICALS | 5.2% | $10.0m | 7,429,590 | 80% | added | |
| 7 | CMPS COMPASS PATHWAYS PLC | Healthcare | 4.2% | $8.1m | 573,086 | -23% | reduced |
| 8 | KYTX KYVERNA THERAPEUTICS INC | 4.1% | $7.9m | 883,198 | 37% | added | |
| 9 | ARTV ARTIVA BIOTHERAPEUTICS IN | 3.5% | $6.8m | 696,436 | 376% | added | |
| 10 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 3.2% | $6.1m | 983,070 | -26% | reduced |
| 11 | AQST AQUESTIVE THERAPEUTICS IN | 3.1% | $6.0m | 1,442,397 | 103% | added | |
| 12 | PALI PALISADE BIO INC | Healthcare | 2.8% | $5.4m | 2,582,388 | 132% | added |
| 13 | IMUX IMMUNIC INC | 2.6% | $5.0m | 325,022 | – | new | |
| 14 | IVA INVENTIVA SA - ADR | 2.5% | $4.8m | 1,281,212 | 77% | added | |
| 15 | SABS SAB BIOTHERAPEUTICS INC | 2.2% | $4.2m | 1,076,578 | 6% | added | |
| 16 | OBIO ORCHESTRA BIOMED HOLDINGS | 2.0% | $3.9m | 896,701 | 0% | held | |
| 17 | CLDX CELLDEX THERAPEUTICS INC | Healthcare | 2.0% | $3.9m | 103,695 | -21% | reduced |
| 18 | ZVRA ZEVRA THERAPEUTICS INC | 1.9% | $3.6m | 253,544 | -10% | reduced | |
| 19 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 1.8% | $3.5m | 357,966 | -6% | reduced |
| 20 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 1.8% | $3.4m | 252,654 | -34% | reduced |
| 21 | OVID OVID THERAPEUTICS INC | Healthcare | 1.6% | $3.0m | 1,115,538 | 21% | added |
| 22 | EYPT EYEPOINT INC | Healthcare | 1.4% | $2.7m | 191,745 | -11% | reduced |
| 23 | UPB UPSTREAM BIO INC | 1.3% | $2.4m | 350,389 | 3% | added | |
| 24 | SCYX SCYNEXIS INC | 1.2% | $2.2m | 543,478 | – | new | |
| 25 | SLN SILENCE THERAPEUTICS PLC | 1.1% | $2.1m | 191,733 | – | new | |
| 26 | LONA LEONABIO INC | 0.7% | $1.4m | 149,279 | 0% | held | |
| 27 | MAZE MAZE THERAPEUTICS INC | Healthcare | 0.7% | $1.3m | 43,798 | 0% | held |
| 28 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.6% | $1.1m | 70,380 | -18% | reduced |
| 29 | SGMT SAGIMET BIOSCIENCES INC-A | Healthcare | 0.5% | $973.0k | 125,878 | – | new |
What did Propel Bio Management, LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| VOR VOR BIOPHARMA INC | 19.5% | $5.6m |
| VRDN VIRIDIAN THERAPEUTICS INC | 14.3% | $4.1m |
| OCULIS HOLDING AG | 11.5% | $3.3m |
| TRVI TREVI THERAPEUTICS INC | 9.3% | $2.6m |
| IMUX IMMUNIC INC | 9.2% | $2.6m |
| CHRS COHERUS ONCOLOGY INC | 8.4% | $2.4m |
| KLRS KALARIS THERAPEUTICS INC | 6.0% | $1.7m |
| UNIQURE NV | 6.0% | $1.7m |
| NUVB NUVATION BIO INC | 4.9% | $1.4m |
| EVMN EVOMMUNE INC | 4.5% | $1.3m |
| ALDX ALDEYRA THERAPEUTICS INC | 4.3% | $1.2m |
| CNTB CONNECT BIOPHARMA HLDGS LTD | 1.9% | $553.9k |
| MSLE SATELLOS BIOSCIENCE INC | 0.2% | $57.1k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 32.8% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Propel Bio Management, LLC's portfolio?
Across every quarter Propel Bio Management, LLC has filed, its median largest position is 17.6% of the book and its median top-ten weight is 63.2%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 12.0 completed holding spells, the median lasted 1.0 quarters; 29.0 positions are still open and their final length is unknown.